In a Nutshell
If you have searched anything like "which BPC-157 is third-party tested" or "is this peptide legit," you have already identified the real problem in this market: there is no uniform FDA-verified human-use quality floor. Two vials can carry the same name, the same stated strength and similar packaging, and one may have been produced under pharmaceutical manufacturing controls while the other was made for laboratory use with no requirement that it be sterile, correctly dosed, or even contain the substance on the label.
The distinction that matters is not brand. It is which regulatory framework the preparation was made under. There are three, and they are not close to equivalent:
- FDA-approved drug products — manufactured under full pharmaceutical controls, reviewed by FDA before sale
- Compounded preparations — made either by a state-licensed pharmacy under section 503A for an individual patient against a prescription, or by an FDA-registered 503B outsourcing facility, which may supply office stock without a patient-specific prescription. Not FDA-approved, but made under pharmacy oversight
- "Research-grade" products — sold online, labeled not for human use, and carrying no regulatory assurance that the finished product was prepared, tested or released for human injection. A seller may commission voluntary testing, but no regulator routinely verifies that the certificate is authentic or that it corresponds to the vial you receive
A seller who cannot tell you which of these applies is telling you something.
One further step that is easy to miss: a pharmacy license does not by itself make every peptide eligible for compounding. The specific substance must also satisfy the statutory requirements — for 503A, a USP/NF monograph, being a component of an FDA-approved drug, or appearing on the 503A Bulks List; for 503B, a separate set of conditions including the clinical-need list. A substance's position under 503A does not carry over to 503B. And FDA nomination categories and advisory-committee recommendations are neither approvals nor authorization to compound.
Why "Research Use Only" Is the Whole Point
The phrase looks like boilerplate, and it matters — but not quite in the way it is usually described.
A product legitimately intended for human use must satisfy requirements for identity, purity, potency and — for injectables — sterility. A laboratory-use label does not establish how a batch was actually manufactured or tested — a seller may test voluntarily, or not at all. What it does establish is that the product is not being supplied with the regulatory assurance applicable to an FDA-approved or compliantly compounded human drug.
What the label does not do is create a safe harbor. FDA determines a product's intended use from the totality of the circumstances — website claims, dosing instructions, testimonials, how the seller actually behaves — not from the disclaimer on the vial. A vendor who prints "not for human use" while publishing injection protocols and benefit claims has not made the sale lawful; that combination can instead support an unapproved-new-drug or misbranding case.
So the disclaimer tells you something real about the absence of regulatory assurance, and nothing reassuring about legality — and nothing definite about actual manufacturing quality either way.
This is why "which brand is best" is not quite the right question. Within that category there is no verified basis on which one brand is better than another, because these products do not undergo routine FDA premarket review — so a brand-level quality claim cannot be assumed from regulatory oversight. Some vendors do commission third-party testing and publish certificates. That is better than nothing, but it is voluntary, unverified by any regulator, and the certificate you are shown may not correspond to the vial you receive.
What Compounding Actually Means
Compounded preparations are frequently described online as though they were generic versions of approved drugs. They are not.
FDA does not review compounded drugs for safety, efficacy or quality before they reach patients. That is not a technicality — it is the defining feature of the category, and any legitimate provider will say so plainly.
What compounding does provide is a chain of accountability that the gray market does not:
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Prepares for | An individual patient, against a prescription | Larger batches; may supply office stock to healthcare facilities |
| FDA registration | Not required to register as an outsourcing facility; state pharmacy licensure applies | Must register with FDA |
| Federal cGMP | Exempt when all section 503A conditions are met; state and professional standards still apply | Required |
| FDA inspection | State boards provide day-to-day oversight; FDA may still conduct surveillance and for-cause inspections | Risk-based FDA inspection |
| Patient-specific prescription | Generally required for an identified patient, subject to anticipatory-compounding rules | Not federally required for office stock |
Neither is FDA-approved in the sense an approved drug is. But a 503A pharmacy operates under state licensure and a 503B outsourcing facility is FDA-registered under a separate federal framework, and both can be identified, inspected and — if they fail — sanctioned. An offshore or opaque online seller may be far harder to identify, inspect and hold accountable, and offers none of the licensure and traceability of a regulated pharmacy pathway.
Where the product is going matters as much as who made it. In California, a pharmacy that compounds sterile injectable preparations must hold a California pharmacy license and a separate sterile compounding pharmacy license from the California State Board of Pharmacy 13. An out-of-state pharmacy shipping such preparations into California must hold both a nonresident pharmacy license and a nonresident sterile compounding pharmacy license, the latter issued only after the Board has inspected the premises 13. A 503B outsourcing facility that supplies California must also hold a California outsourcing-facility license — FDA registration alone is not sufficient 13.
The ingredient has to qualify too. Under section 503A, a bulk drug substance may be used in compounding only if, in this order, it complies with an applicable USP/NF monograph; or, if there is none, it is a component of an FDA-approved drug; or, if neither applies, it appears on FDA's 503A Bulks List 14. These are ingredient requirements — every other condition of section 503A still has to be met. FDA's interim enforcement policy, under which nominated substances are sorted into Categories 1, 2 and 3, is an exercise of enforcement discretion while FDA evaluates nominations; it is not a determination of statutory eligibility and it is not drug approval 15. Neither a nomination nor a favorable advisory-committee vote, by itself, authorizes anyone to compound a substance.
The Four Questions Worth Asking
If you are evaluating any peptide product or provider, these get to the substance quickly.
1. Is there a prescriber, and did they assess me? A compounded prescription preparation requires a prescription from a licensed clinician who has evaluated you. A questionnaire can form part of an appropriate evaluation when a licensed clinician reviews it and meets the applicable standard of care — but a form on its own does not establish that the evaluation was adequate. If nobody reviewed your medications, history and relevant labs, no one has checked whether this is safe for you specifically.
2. Which pharmacy or facility prepared it, and is it licensed? A responsible provider should tell you. State boards of pharmacy publish licensee lookups; FDA publishes registered 503B outsourcing facilities. A provider unwilling to name the source is asking for trust it has not earned.
3. What testing was done on this batch? The meaningful questions are identity (is it the stated substance), potency (is it the stated strength), sterility (for injectables), and endotoxin. Ask whether testing is performed per batch and whether results are available.
4. What happens if something goes wrong? With a licensed prescriber and pharmacy there is a clinical pathway — someone to call, a record of what you received, an adverse-event reporting route. For any online provider, check that the prescriber and dispensing facility are identified, that a treatment record is kept, and that clinical follow-up is available.
Red Flags — Do Not Proceed
- "Research use only" or "not for human use" on anything a seller implies you should inject
- An injectable peptide shipped directly to you with no prescriber or documented clinical pathway. Note the nuance: a 503A preparation is generally compounded for an identified patient against a valid prescription, while a 503B outsourcing facility may supply office stock without a patient-specific prescription — so "no prescription" alone is not proof of illegality. What matters is whether there is an authorized pathway at all
- An unverified third-party marketplace or social-media listing. Confirm the actual seller — not the hosting platform — is a licensed pharmacy or authorized facility following the applicable prescription or office-stock pathway
- Dosing protocols supplied by the seller rather than a clinician
- No named pharmacy or manufacturing facility
- Certificates of analysis that are undated, unattributed, or not batch-specific
- Claims a peptide is "FDA approved" when it is not — verify the specific substance and route
- Price is not proof of quality in either direction. Compare the exact product, concentration, quantity, pharmacy, testing, clinical services and follow-up rather than treating a high or low price as evidence
Seek medical care promptly if after using any peptide you develop fever, spreading redness, swelling or pain at an injection site, difficulty breathing, chest pain, severe abdominal pain, or a widespread rash. Non-sterile injectable preparations can cause local or systemic infection. Severe allergic or immune reactions are a separate risk, arising from the active ingredient, excipients, aggregates, contaminants or peptide-related impurities.
What FDA Has Actually Said About Peptide Quality
FDA's published reasoning on peptide bulk substances is worth reading directly, because it is more specific than most summaries suggest. Across the peptides it has evaluated, the recurring concerns are 1:
- Immunogenicity — peptides can aggregate, and aggregated peptide plus related impurities can trigger an immune response, in some cases against the body's own corresponding hormone
- Characterization difficulty — several contain unnatural amino acids, making it genuinely hard to confirm what a given preparation contains
- Absent human safety data — for many, FDA's position is that it "lacks sufficient information to know whether the drug would cause harm if administered to humans"
That last point deserves emphasis because it is routinely misrepresented in both directions. It is not a finding that these substances are dangerous. It is a finding that the work establishing their safety has not been done. Absence of proven harm is not reassurance, and the finding should not be read as one.
These concerns are about the substances themselves. They apply on top of the manufacturing-quality questions above — which is why an unregulated preparation of a poorly characterized peptide compounds two separate problems.
What FDA Warning Letters and Recall Notices Show
Everything above describes the framework. This is what the framework has actually caught — and how to read it, because the two kinds of public record involved are not the same thing.
A warning letter states FDA's own inspection findings and legal position. A recall notice on FDA's website is usually the company's announcement, which FDA posts as a public service with an explicit note that it does not endorse the product or the company. Both are useful. Only the first is FDA telling you what it found.
Why these three, and what they cannot tell you. They were chosen because each illustrates a different finished-product quality problem, and because this hub discusses sermorelin — not because sermorelin fails more often than anything else compounded. They are illustrative, not a complete list, and they cannot be used to work out how often failures happen: there is no denominator — no total of lots compounded, prescriptions filled or patients exposed — and there are further records beyond these (a fourth pharmacy recalled all unexpired lyophilized sermorelin and HCG in 2016, recorded in a later FDA warning letter 12).
Each firm is described by state rather than name: these are dated records of specific inspections and recalls, not verdicts on any business as it operates today. The full citations are in the references if you want to read them. Treat what follows as three worked examples of three different problems.
1. A confirmed sterility-test failure. (FDA warning letter.) A New Jersey compounding pharmacy recalled sermorelin/GHRP-6 injection 6 mg/3 mg on August 1, 2016 after a sterility failure — a lot that failed the applicable test. FDA's October 2017 warning letter cited serious deficiencies in the firm's practices for producing sterile drug products 7.
2. Lack of sterility assurance. (Company announcement, then an FDA warning letter — one episode, two records.) Following a 2021 FDA inspection, an Arizona pharmacy recalled three lots of sermorelin/ipamorelin and four of AOD-9604 for lack of sterility assurance 9. FDA's January 2022 warning letter then set out the inspection findings, including that vials over which the pharmacist-in-charge had blocked first air were not discarded but used to prepare a sermorelin/ipamorelin lot 10. The same firm had recalled all sterile products, including six lots of sermorelin with GHRP-2, in 2019 8.
This is a different finding from the first one. Lack of sterility assurance means the process could not be relied upon to produce a sterile product — not that a particular vial was proven contaminated.
3. An out-of-specification result. (Company announcement.) A Florida pharmacy recalled 11 lots in March 2022, including two lots of sermorelin acetate 9 mg, because the products were out of specification 11. The notice does not say which specification the sermorelin lots failed. Its risk statement describes incorrect strength or reconstitution rate as possible consequences of out-of-specification injectables generally, and that is as far as the record goes.
Several of these involved multi-ingredient preparations — sermorelin with GHRP-6, with GHRP-2, with ipamorelin. That is worth understanding structurally rather than statistically: in a combination product every component must be independently eligible and correctly identified, and the finished blend needs its own compatibility, potency, stability, sterility and beyond-use support. Regulatory history for one component does not validate the mixture. (Note this is a point about the product, not the pharmacy: in 2017 FDA also found that GHRP-6 did not meet a section 503A bulk-substance eligibility route at that time — an ingredient-eligibility question, which is separate from whether a batch was made correctly.)
One common reassurance does not survive this record. When that firm told FDA it had not failed a sterility test in five years, the agency's reply was direct: "a passing sterility test does not prove the sterility of each unit of each lot you produce and should not be solely relied upon as an indication of product sterility" 10. Batch testing is necessary but not sufficient — which is why question 3 above asks what was tested on your batch, and why a certificate belonging to some other batch answers nothing.
How to read all of this. None of it shows that compounded sermorelin is unusually dangerous, that these pharmacies are representative, or that sermorelin itself caused any of these failures — these are manufacturing and facility problems, not pharmacology. The two company recall notices each stated that no related adverse events had been reported at the time of publication; the 2017 warning letter makes no equivalent statement, and silence is not the same as zero.
What the records do show is two things at once. Licensed compounding facilities can and do have serious quality failures. And regulated pathways are what make inspection, public warning, recall and correction possible at all. Licensure buys accountability and a detection mechanism — it does not guarantee any individual vial. For an opaque online seller, no comparable failure rate can even be calculated: there is no denominator and no equivalent reporting route, and that absence is not evidence that such products fail less often.
What You Can Do About It
If you are already using a peptide obtained outside clinical channels: tell a clinician. Not to be lectured — because they cannot assess interactions, monitor for adverse effects, or interpret your labs without knowing. Clinicians who work in this area are generally more interested in managing risk than in judgment.
If you are considering starting: begin with the clinical question rather than the product. What are you actually trying to change — recovery, sleep, body composition, energy? A proper workup frequently identifies something treatable that a peptide would not have addressed, and occasionally identifies a reason a peptide would be a bad idea for you specifically.
If you are comparing providers: ask the four questions above. The answers separate clinical programs from storefronts quickly.
Get Started with JumpstartMD
This market is confusing, so we would rather give you the framework and let you apply it — including to us.
JumpstartMD was founded in 2007 by Stanford-trained physicians. Our programs are built around labs, hormones and body composition, and our outcomes have been published in the peer-reviewed literature. You are seen face-to-face by licensed clinicians — in person at 14 California locations or online across California — and every plan starts with a clinical assessment including 60-biomarker lab screening and InBody® body composition scanning. Medication decisions, where they apply, are made by a clinician against your full history and medication list, with contraindication screening before anything is prescribed. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Sermorelin is supplied as a compounded preparation, not an FDA-approved finished drug: GEREF was historically approved for diagnostic use and pediatric growth hormone deficiency — not adult sleep, recovery, body-composition or healthy-aging goals — and controlled evidence for those adult outcomes remains limited.
Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- Are Peptides Legal in the US? The FDA Status, Explained — the regulatory picture and what the July 2026 vote actually decided
- Sermorelin — mechanism, evidence and current regulatory status
- BPC-157 — the most-searched peptide, and what the evidence shows
- Peptide Therapy: What It Is and Who It's For — the overview
- Medically Supervised GLP-1 Care — the same supervision question in an approved-drug category
Frequently Asked Questions
How do I know if peptides are legit?
Work out which framework the preparation was made under. FDA-approved products follow their approved prescription pathways. 503A compounding generally requires a valid prescription for an identified patient. A 503B outsourcing facility may distribute office stock without patient-specific prescriptions. None of those pathways authorizes an online seller to ship an unapproved injectable for self-treatment. Products labeled "research use only" come through none of them — no sterility, potency or identity requirement applies to them. Ask who prescribed it, which licensed facility prepared it, and what batch testing was performed.
What's the difference between research-grade and pharmaceutical-grade peptides?
Research-grade peptides are manufactured for laboratory use and carry no requirement to be sterile, accurately dosed, or free of contaminants — which is why they are labeled not for human use. Pharmaceutical-grade preparations are made under manufacturing controls appropriate for human administration. The names sound like quality tiers. They are descriptive terms, not legal categories — neither establishes whether a product may be supplied for human use. The legal question is whether the exact finished product is an FDA-approved drug, a compounded drug qualifying under 503A or 503B, or an unapproved new drug marketed for human use.
Is BPC-157 sold on Amazon or by online vendors legitimate?
A marketplace listing is not by itself a lawful prescription pathway: check that the seller is an identified licensed dispensing pharmacy and that prescribing requirements have been met. Peptides sold outside that route commonly rely on "not for human use" labeling. There is no regulatory assurance of what such a vial contains. BPC-157 is not an FDA-approved drug. On July 23, 2026 the FDA advisory committee voted to recommend including it on the 503A Bulks List specifically — a recommendation that is non-binding, does not touch 503B, and does not itself authorize compounding or change its approval status. FDA must take further action before anything is added to the final list.
Which brand of peptide is best?
Within the research-grade market the question does not have a verifiable answer, because these products undergo no routine premarket review and opaque sellers may offer little traceability. Regulators can and do act where intended human use is established — but that is enforcement after the fact, not a check on the vial you were sent. Some vendors publish voluntary third-party certificates of analysis, which is better than nothing but is unverified and may not correspond to the vial you receive. The meaningful distinction is regulatory category, not brand.
Does third-party testing make a peptide safe?
It addresses one problem — whether the vial contains what the label claims — and not others. It does not establish that the substance is safe or effective in humans, it does not guarantee sterility unless sterility was specifically tested, and voluntary testing is not independently verified. It is a partial answer to a narrow question.
Are compounded peptides FDA approved?
No. FDA does not review compounded preparations for safety, efficacy or quality before they reach patients. Compounding provides accountability — licensed facilities, a prescriber, a record — but it is not equivalent to drug approval, and any provider suggesting otherwise is misdescribing it.
Why are clinic-supplied peptides more expensive than online ones?
Sterile pharmaceutical manufacturing, batch testing, licensed facilities and clinical assessment all carry real cost, so a price far below clinical channels is worth asking about. It does not by itself prove that any particular control was skipped. Compare the exact product, concentration, quantity, pharmacy, testing, clinical services and follow-up rather than reading price as a proxy for quality.
References
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, "Compounding and the FDA: Questions and Answers." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, "Registered Outsourcing Facilities." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, "Human Drug Compounding." [Online]. Available: https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding [Accessed: Jul. 25, 2026]. ↩
- Regulatory Affairs Professionals Society, "FDA advisory committee backs two controversial peptides," Jul. 2026. [Online]. Available: https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html [Accessed: Jul. 25, 2026]. ↩
- California State Board of Pharmacy, "2026 Lawbook for Pharmacy" (Rev. 7/2026): Business and Professions Code §4127.1 (License for Compounding Sterile Drug Products); California Code of Regulations, Title 16, Division 17, Article 4.5 (Nonsterile Compounding, §1735 et seq.) and Article 4.6 (Sterile Compounding, §1736 et seq.). [Online]. Available: https://www.pharmacy.ca.gov/laws_regs/lawbook.pdf [Accessed: Oct. 5, 2026]. ↩
- U.S. Food and Drug Administration, "Town and Country Compounding and Consultation Services, LLC — 518371 — 10/17/2017," Warning Letter, Oct. 17, 2017. [Online]. Available: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/town-and-country-compounding-and-consultation-services-llc-518371-10172017 [Accessed: Jul. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of All Sterile Compounded Drug Products Due to a Lack of Sterility Assurance," Oct. 10, 2019. [Online]. Available: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/innoveix-pharmaceuticals-inc-issues-voluntary-recall-all-sterile-compounded-drug-products-due-lack [Accessed: Jul. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Innoveix Pharmaceuticals, Inc. Issues Voluntary Recall of All Sterile Compounded Drug Products Due to a Lack of Sterility Assurance," Jul. 12, 2021. [Online]. Available: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/innoveix-pharmaceuticals-inc-issues-voluntary-recall-all-sterile-compounded-drug-products-due-lack-0 [Accessed: Jul. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Innoveix Pharmaceuticals Inc — 624782 — 01/26/2022," Warning Letter, Jan. 26, 2022. [Online]. Available: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/innoveix-pharmaceuticals-inc-624782-01262022 [Accessed: Jul. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Olympia Pharmacy Issues Voluntary Nationwide Recall of Seven Compounded Products Due to Being Out-of-Specification," Mar. 10, 2022. [Online]. Available: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/olympia-pharmacy-issues-voluntary-nationwide-recall-seven-compounded-products-due-being-out [Accessed: Jul. 26, 2026]. ↩
- U.S. Food and Drug Administration, "Talon Compounding Pharmacy — 522630 — 10/03/2017," Warning Letter, Oct. 3, 2017. [Online]. Available: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/talon-compounding-pharmacy-522630-10032017 [Accessed: Jul. 26, 2026]. ↩
- California Business and Professions Code, §4127.1 (sterile compounding pharmacy license), §4127.2 (nonresident sterile compounding pharmacy license), §4112 (nonresident pharmacy license) and §4129 (outsourcing facility license). [Online]. Available: https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?lawCode=BPC§ionNum=4127.1. [Accessed: Oct. 6, 2026]. See also the California State Board of Pharmacy lawbook 6. ↩
- 21 U.S.C. §353a(b)(1)(A) — Pharmacy compounding: bulk drug substances. [Online]. Available: https://www.law.cornell.edu/uscode/text/21/353a [Accessed: Oct. 6, 2026]. ↩
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (interim policy categories; content current as of Apr. 22, 2026). [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Oct. 5, 2026]. ↩